Dyne Appoints Brumm President & CEO, Subramanian Shifts to CSO

Joshua Brumm has been appointed president and CEO of Dyne Therapeutics. Romesh Subramanian, Dyne’s founder and former CEO, has shifted to a new role as chief scientific officer. Brumm will join Waltham, MA-based Dyne from Kaleido Biosciences (NASDAQ: [[ticker:KLDO]]), where he has been chief financial officer since last year. Kaleido said Brumm’s last day will be Oct. 11. Dyne, which is developing antibody drugs to treat rare muscular disorders, closed $50 million in Series A financing in April.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.